By John Carroll Valeant Pharmaceuticals ($VRX) CEO Michael Pearson didn’t take much time to get over the loss of Cephalon ($CEPH). Ever the hunter, Pearson tells Reuters that “time is the enemy.” And right now the clock is ticking down to another takeover deal. This next one is likely to be a specialty pharma player …
By Tracy Staton Now that Teva Pharmaceutical Industries has snatched Cephalon, what’s next for would-be suitor Valeant Pharmaceuticals? More deals, naturally. After all, Valeant CEO Michael Pearson said from the get-go that Cephalon wasn’t the only M&A prize in the pharma world. And Pearson has made quite clear that making deals is his answer to …
By John Carroll Rebuffed after making a private overture, Canada’s Valeant Pharmaceuticals ($VRX) has gone hostile in its pursuit of Cephalon, offering $5.7 billion for the business and threatening to walk in a month if investors don’t take the money and run. If it’s successful, Valeant will gobble up an operation that boasts of a blockbuster …
By John Carroll Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The …
